Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Ivermectin  COVID-19 treatment studies for Ivermectin  C19 studies: Ivermectin  Ivermectin   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
Ivermectin, A Reanalysis of the Data
Marik et al., American Journal of Therapeutics, doi:10.1097/MJT.0000000000001443 (meta analysis)
Marik et al., Ivermectin, A Reanalysis of the Data, American Journal of Therapeutics, doi:10.1097/MJT.0000000000001443 (meta analysis)
Sep 2021   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Updated meta analysis showing no significant change if Elgazzar et al. is excluded.
Currently there are 95 ivermectin studies and meta analysis shows:
OutcomeImprovement
Mortality51% lower [37‑62%]
Ventilation29% lower [13‑42%]
ICU admission41% lower [16‑58%]
Hospitalization34% lower [20‑45%]
Cases78% fewer [67‑85%]
Marik et al., 2 Sep 2021, peer-reviewed, 2 authors.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperIvermectinAll
Abstract: Letters to the Editor e579 Queen Mary University of London London, United Kingdom The authors have no conflicts of interest to declare. REFERENCES 1. Bryant A, Lawrie TA, Dowswell T, et al. Ivermectin for prevention and treatment of COVID-19 infection: a systematic review, meta-analysis, and trial sequential analysis to inform clinical guidelines. Am J Ther. 2021;28:e434–e460. 2. Roman YM, Burela PA, Pasupuleti V, et al. Ivermectin for the treatment of COVID-19: a systematic review and metaanalysis of randomized controlled trials.,Clin Infect Dis. 2021; ciab591. doi: 10.1093/cid/ciab591. 3. Crawford M. The Meta-Analytical Fixers: An Ivermectin Tale; 2021. Available at: https://roundingtheearth. substack.com/p/the-meta-analytical-fixers-anivermectin. Accessed July 7, 2021. 4. Neil M, Fenton NE, Bayesian Hypothesis Testing and Hierarchical Modelling of Ivermectin Effectiveness in Treating Covid-19, 2021. Available at: http://dx.doi.org/10. 13140/RG.2.2.19703.75680. 5. Niaee MS, Gheibi N, Namdar P, et al. Ivermectin as an adjunct treatment for hospitalized adult COVID-19 patients: a randomized multi-center clinical trial. Asian Pac J Trop Med. 2021;14:266. 6. Elgazzar A, Hany B, Youssef SA, et al. Efficacy and Safety of Ivermectin for Treatment and Prophylaxis of COVID-19 Pandemic; 2020. Available at: https://www.researchsquare. com/article/rs-100956/v2. Ivermectin, A Reanalysis of the Data To the Editor: Our article entitled “Review of the Emerging Evidence Demonstrating the Efficacy of Ivermectin in the Prophylaxis and Treatment of COVID-19” was recently published in the American Journal of Therapeutics.1 Our article included randomized and observational trial meta-analyses on the efficacy of ivermectin for the prophylaxis and treatment of COVID-19. Recently, the study conducted by Elgazzar et al2 has come under scrutiny with accusations of scientific misconduct. His paper was apparently retracted without his knowledge and without giving him the opportunity to defend these serious claims. This situation is most unfortunate. While this issue is being resolved, we decided to redo the original meta-analyses excluding this study. The summary point estimates were largely unaffected when the study by Elgazzar et al was removed. The revised forest plots are provided below (Figures 1–3). FIGURE 1. Meta-analysis of ivermectin prophylaxis trials in COVID-19. Symbols: Squares indicate treatment effect of an individual study. Large diamond reflects summary of study design immediately above. Size of each symbol correlates with the size of the CI around the point estimate of treatment effect with larger sizes indicating a more precise CI. CI, confidence interval; OBS, observational study; RCT, randomized controlled trial. www.americantherapeutics.com American Journal of Therapeutics (2021) 28(5) Copyright © 2021 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited. e580 Letters to the Editor FIGURE 2. Meta-analysis of the outcome of time to clinical recovery from controlled trials of ivermectin treatment in COVID19. Symbols: Squares indicate treatment effect of an individual study. Large diamond reflects summary of study design immediately above. Small diamond indicates sum effect of all trial designs. Size of each symbol correlates with the size of the CI around the point estimate of treatment effect with larger sizes indicating a more precise CI. CI, confidence interval. FIGURE 3. Meta-analysis of the..
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit